药师帮预计净利不少于2000万元,九典制药1亿-1.5亿元回购股份,海普瑞1类新药获批临床,昂利康1类新药申报临床

谈医说药
18 Feb

昂利康:公司收到国家药监局签发的注射用ALK-N001境内生产药品注册临床试验《受理通知书》。注射用ALK-N001是一种全球创新的肿瘤微环境激活型小分子偶联药物,具有明显的抑制肿瘤作用和良好的安全性,有望为晚期实体瘤患者提供新的治疗选择。药师帮:预计截至2024年12月31日止年度,公司将实现不少于2000万元的净利润,而截至2023年12月31日止年度则为净亏损31.89亿元。这一盈利预警主要...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10